Drugs / MKP10241
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07098663 | Aug 2025 → Jan 2026 overdue | obesity disorder, type 2 diabetes mellitus | Mankind Pharma Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MKP10241 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07098663 ↗ |
| Route | Oral | “Oral liquid suspension of unit dose strength 6.6 mg/mL” NCT07098663 ↗ |